Amylyx Pharmaceuticals, Inc. — Form D/A
Amylyx Pharmaceuticals, Inc. of CAMBRIDGE, MA, a company, filed a Form D amendment with the SEC on 2019-12-31. The offering totals $15.0M, of which $937K was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2019-12-31
- Form: D/A
- Accession: 0001658551-19-000003
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $15.0M
- Amount sold: $937K
- Remaining: $14.1M
- Minimum investment: $10K
- Investors: 8
- Date of first sale: 2019-12-17
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-356768
Issuer
- Name: Amylyx Pharmaceuticals, Inc.
- CIK: 0001658551
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2014
- Address: 43 THORNDIKE STREET, CAMBRIDGE, MA, 02141
- Phone: 617-683-0917
Officers, directors & promoters (13)
| Name | Role | Location |
|---|
| Joshua Cohen | Director | Coral Gables, FL |
| Joshua Cohen | Executive Officer | Coral Gables, FL |
| Peter Finn | Executive Officer | Watertown, MA |
| Isaac Cheng | Director | Portland, ME |
| Stephen Chubb | Director | BOSTON, MA |
| Justin Klee | Director | Cambridge, MA |
| Justin Klee | Executive Officer | Cambridge, MA |
| George Milne | Director | Cambridge, MA |
| Walter Gilbert | Director | Cambridge, MA |
| Felix Von Coerper | Director | Cambridge, MA |
| Stephen D Chubb | Director | Cambridge, MA |
| George M Milne, PH.D. | Director | Cambridge, MA |
| Peter B Finn | Executive Officer | Boston, MA |
Other filings by this issuer (9)
More